The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | R | Respiratory system | |
| 2 | R03 | Drugs for obstructive airway diseases | |
| 3 | R03D | Other systemic drugs for obstructive airway diseases | |
| 4 | R03DX | Other systemic drugs for obstructive airway diseases | |
| 5 | R03DX05 | Omalizumab |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| PAREN - Parenteral | 16 mg |
| Active Ingredient | Description | |
|---|---|---|
| Omalizumab |
Omalizumab is a recombinant DNA-derived humanised monoclonal antibody that selectively binds to human immunoglobulin E (IgE) and lowers free IgE levels. The antibody is an IgG1 kappa that contains human framework regions with the complementary-determining regions of a murine parent antibody that binds to IgE. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| XOLAIR 150 mg Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
| XOLAIR 75 mg Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.